RICHMOND, Calif., March 8, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that new data from its program to develop a 'functional cure' for HIV/AIDS were described in two presentations at the 19th Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle from March 5 to March 8, 2012.
"These data differentiate SB-728-T from other novel therapies as a feasible approach to controlling HIV/AIDS," said Ronald Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA and a principal investigator in Sangamo's SB-728-T studies. "The results suggest that SB-728-T has a positive effect on immune health of HIV-infected patients and this effect is persistent for over a year in some subjects. Most importantly, SB-728-T treatment provides HIV-resistant T-cells that are capable of mounting an immune response to an inflammatory event in lymphoid tissues and has yielded encouraging effects on HIV viral load when antiretroviral drugs are withdrawn during a treatment interruption."
"These data add to our understanding of the positive viral load changes in SB-728-T-treated subjects, and suggest that an early cytokine burst may initiate the dramatic and prolonged increase in CD4 counts observed following SB-728-T treatment," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "They also confirm that SB-728-T meets key requirements for our strategy for a 'functional cure' for HIV, by demonstrating durable engraftment and prolonged trafficking and dynamic immunological responsiveness in the gut mucosa. Together, these data further validate our strategy for the continued development of this ZFP Therapeutic as a 'functional cure' for HIV in two ongoing Phase 2 clinical trials designed to extend the observation of a statistically significant correlation between levels of bi-allelic modification of CD4 T cells and viral load reductions during treatment interruptions in HIV infection. The first study builds on the approximate doubling of bi-allelic engraftment that can be achieved in CCR5 delta-32 heterozygotes and seeks to confirm the occurrence of aviremia during treatment interruption as observed in one such patient in our Phase 1 program. The other clinical trial will examine the ability of a lymphopenic preconditioning regimen to enhance bi-allelic engraftment, and reduce viral load during treatment interruption, in non-CCR5-mutated HIV subjects."Clinical Trial Data Summary Abstract # 155 "Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T-cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load (VL) in HIV-infected Subjects" - Thursday, March 8, 2012 21 HIV-infected subjects were enrolled in Phase 1 clinical studies at the University of Pennsylvania and in California (SB-728-902) and received a single dose of SB-728-T (5 to 30 billion cells). All subjects were taking highly active antiretroviral therapy (HAART) and had stably controlled undetectable levels of HIV in their blood. Subjects were classified into two groups based on their CD4+ T-cell counts: one group of 15 subjects, with CD4+ T-cell counts below 500 cells/ ul designated Immune Non-Responders (INR), and a second group of six subjects with CD4+ T-cell counts of greater than 450 cells/ ul designated Immune Responders (IR). One month after SB-728-T treatment, six subjects in the INR group enrolled in the University of Pennsylvania study underwent a 12-week treatment interruption (TI) of their HAART. The studies evaluated safety and tolerability, changes in CD4+ T-cell counts and the ratio of CD4+ to CD8+ T-cells as well as persistence of SB-728-T in the blood and trafficking of these ZFN-modified cells into gut-associated lymph tissue. In addition, viral DNA and changes in viral load (VL), as measured by HIV-RNA, were measured during the TI in the six INR subjects.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV